Cougar Biotechnology Inc. (CGRB) said that a multicenter phase II study of abiraterone acetate demonstrates anti-tumor activity in docetaxel pre-treated castration-resistant prostate cancer patients.
The company presented the results from ongoing phase II clinical trials of Cougar's investigational drug CB7630 at the 2009 ASCO annual meeting.
In the trial, CB7630 is administered orally, once daily, to patients with CRPC who have failed treatment with androgen deprivation therapy and failed treatment with first-line docetaxel-based chemotherapy.
Of the 33 evaluable patients, treatment with CB7630 plus prednisone resulted in radiologic disease control in 28 patients with partial responses in 9 patients and stable disease in 19 patients, the company said.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.